Entasis Therapeutics to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 21 2017 - 7:00AM
Business Wire
Entasis Therapeutics, a leader in the discovery and development
of breakthrough anti-infective products, today announced two oral
presentations at the 27th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID), which is being held
April 22 – 25 in Vienna, Austria. Both presentations will highlight
the preclinical profile of ETX2514, Entasis’ next-generation
beta-lactamase inhibitor with an expanded spectrum of activity
against Class A, C, and D beta-lactamases, as well as that of
ETX2514SUL, the combination of ETX2514 with sulbactam which is
being developed for the treatment of A. baumannii infections.
ETX2514SUL is currently in Phase 1 clinical trials.
Details of the presentations are as follows:
Title: ETX2514: Responding to the global threat of
nosocomial multidrug and extremely drug resistant Gram-negative
pathogensDate and Time: Monday April 24, 9:00
AMLocation: Hall KAbstract #: 4097Presenter:
Dr. Ruben Tommasi
Title: Restoration of sulbactam activity against
multidrug resistant Acinetobacter baumannii by the novel, broad
spectrum β-lactamase inhibitor ETX2514 correlates with β-lactamase
inhibition in vitro and in vivoDate and Time: Monday April
24, 9:36 AMLocation: Hall KAbstract #:
5942Presenter: Dr. Alita Miller
About ETX2514ETX2514 is a potent and broad spectrum
inhibitor of class A, C, and D beta-lactamases. ETX2514 restores
the in vitro activity of multiple beta-lactams against
Gram-negative, multi-drug resistant (MDR) pathogens. Entasis
Therapeutics is developing ETX2514SUL, the combination of ETX2514
and sulbactam, for the treatment of severe A. baumannii infections.
A. baumannii is a Gram-negative bacterium that causes severe
infections which are associated with high mortality rates. A.
baumannii infections are frequently multi-drug resistant and there
is an urgent need to identify new safe and effective agents to
treat affected patients. Sulbactam is a generic beta-lactam which
has intrinsic activity against A. baumannii but suffers from
widespread beta-lactamase-mediated resistance. In preclinical
studies, ETX2514 restores sulbactam’s antimicrobial activity
against A. baumannii. ETX2514SUL is currently in Phase 1 clinical
trials.
About Entasis Therapeutics Inc.Entasis Therapeutics is
developing a portfolio of innovative cures for serious
drug-resistant bacterial infections, a global health crisis
affecting the lives of millions of patients. Entasis’
anti-infective discovery platform has produced a pipeline of
meaningfully differentiated programs which target serious bacterial
infections, including ETX2514SUL (targeting infections caused by
Acinetobacter baumannii infections) and zoliflodacin (targeting the
treatment of Neisseria gonorrhoeae infections) currently in the
clinic. www.entasistx.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170421005095/en/
Company ContactEntasis TherapeuticsKyle Dow,
781-810-0114kyle.dow@entasistx.comorMedia ContactMacDougall
Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.com